ArticleNature communications2022
Cost-effectiveness of routine adolescent vaccination with an M72/AS01
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Should routine HPV vaccination programs include males 25-29 years? A systematic review and global meta-analysis.Journal of translational medicine · 2025Pooled it
- Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.PharmacoEconomics · 2024Pooled it
- Global burden and trend of tuberculosis in children and adolescents (under 15 years old) from 1990 to 2021, with projections to 2040.Frontiers in public health · 2025Article
- Driving innovation from discovery to access: Meeting report of the 7Gates open research · 2025Article
- Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study.BMJ public health · 2024Article
- Estimating the Potential Public Health Value of BCG Revaccination.The Journal of infectious diseases · 2024Article
- Immunoinformatics and structural aided approach to develop multi-epitope based subunit vaccine against Mycobacterium tuberculosis.Scientific reports · 2024Article
- Mapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review.PLOS global public health · 2024Article
- Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report.Frontiers in tuberculosis · 2024Article
- Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies.Vaccines · 2023Review
- Establishment of an indirect ELISA for Mycobacterium tuberculosis MTB39A protein antibody.Applied microbiology and biotechnology · 2023Article
- Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study.BMJ global health · 2023Article
- A Multistage Antigen Complex Epera013 Promotes Efficient and Comprehensive Immune Responses in BALB/c Mice.Vaccines · 2023Article
- Article
- Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis.NPJ vaccines · 2022Article
- It Takes a Village: The Multifaceted Immune Response toFrontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The M72/AS01
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.